On Wednesday, the shares of Lupin closed at Rs 1112.95, up by 2.89% from its previous closing of Rs 1081.70 on the BSE. Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Doxycycline Hyclate Delayed-Release Tablets USP, 50 mg, 60 mg, 75 mg, 80 …